Expression of STAT1 is positively correlated with PD-L1 in human ovarian cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Expression of STAT1 is positively correlated with PD-L1 in human ovarian cancer
Authors
Keywords
-
Journal
CANCER BIOLOGY & THERAPY
Volume 21, Issue 10, Pages 963-971
Publisher
Informa UK Limited
Online
2020-10-12
DOI
10.1080/15384047.2020.1824479
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Enhancing anti-tumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
- (2019) K M Heinhuis et al. ANNALS OF ONCOLOGY
- Biological Insights into Chemotherapy Resistance in Ovarian Cancer
- (2019) Michelle A. Glasgow et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
- (2019) Radhakrishnan Ramchandren et al. JOURNAL OF CLINICAL ONCOLOGY
- Progesterone Receptor Attenuates STAT1-Mediated IFN Signaling in Breast Cancer
- (2019) Merit L. Goodman et al. JOURNAL OF IMMUNOLOGY
- Emerging strategies in cancer therapy combining chemotherapy with immunotherapy
- (2019) Qiuhua Luo et al. CANCER LETTERS
- Immune checkpoint inhibitors: The linchpins of modern immunotherapy
- (2019) Breelyn A. Wilky IMMUNOLOGICAL REVIEWS
- Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment
- (2019) Rachael M. Zemek et al. Science Translational Medicine
- Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy
- (2019) Yan-ping Xu et al. JOURNAL OF CLINICAL INVESTIGATION
- Immunotherapy in Ovarian Cancer: Are We There Yet?
- (2019) Lana E. Kandalaft et al. JOURNAL OF CLINICAL ONCOLOGY
- Current strategies for different paclitaxel-loaded Nano-delivery Systems towards therapeutic applications for ovarian carcinoma: A review article
- (2019) Alaa M. Khalifa et al. JOURNAL OF CONTROLLED RELEASE
- Focal Adhesion Kinase in Ovarian Cancer: A Potential Therapeutic Target for Platinum and Taxane-Resistant Tumors
- (2018) Arkene Levy et al. CURRENT CANCER DRUG TARGETS
- Increased STAT1 Expression in High Grade Serous Ovarian Cancer Is Associated With a Better Outcome
- (2018) Juliana A. Josahkian et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women
- (2018) Anne M. Mills et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
- (2018) James Larkin et al. JOURNAL OF CLINICAL ONCOLOGY
- Physical interaction of STAT1 isoforms with TGF-β receptors leads to functional crosstalk between two signaling pathways in epithelial ovarian cancer
- (2018) Xiaoling Tian et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
- (2018) Maureen L. Drakes et al. Journal of Ovarian Research
- The Role of Inflammation and Inflammatory Mediators in the Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer
- (2018) Sudha Savant et al. Cancers
- Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma
- (2018) Michaël Cerezo et al. NATURE MEDICINE
- Preserved Renal-Allograft Function and successful treatment of metastatic Merkel cell cancer post Nivolumab therapy
- (2018) Priyamvada Singh et al. TRANSPLANTATION
- Prognostic value of tumor PD-L1 expression combined with CD8 + tumor infiltrating lymphocytes in high grade serous ovarian cancer
- (2017) Qiaohong Wang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
- (2017) Jun Zhu et al. Journal of Gynecologic Oncology
- FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy
- (2017) Yang‐Min Ning et al. ONCOLOGIST
- Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy
- (2017) Mengjiao Li et al. Journal of Ovarian Research
- Clinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma
- (2017) Jun Zhu et al. PLoS One
- Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)
- (2016) S J L Mesnage et al. ANNALS OF ONCOLOGY
- Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer
- (2016) Jayanta Chatterjee et al. CLINICAL CANCER RESEARCH
- PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer
- (2016) John R. Webb et al. GYNECOLOGIC ONCOLOGY
- FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
- (2016) Joohee Sul et al. ONCOLOGIST
- Clinical relevance of expression of B7-H1 and B7-H4 in ovarian cancer
- (2016) MEI XU et al. Oncology Letters
- Erratum: A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer
- (2015) M Koti et al. BRITISH JOURNAL OF CANCER
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
- (2015) Silvia Darb-Esfahani et al. Oncotarget
- PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer
- (2015) J. R. Webb et al. Cancer Immunology Research
- High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer
- (2014) Piotr Tymoszuk et al. BMC CANCER
- Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma
- (2013) C Gordziel et al. BRITISH JOURNAL OF CANCER
- Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer
- (2013) Christian J. Maine et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- STAT1 activation regulates proliferation and differentiation of renal progenitors
- (2010) Honghe Wang et al. CELLULAR SIGNALLING
- Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
- (2010) Junko Matsuzaki et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cross-regulation of Signaling Pathways by Interferon-γ: Implications for Immune Responses and Autoimmune Diseases
- (2009) Xiaoyu Hu et al. IMMUNITY
- Ups and downs: The STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling
- (2008) Gabriella Regis et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now